CNDA grants rapid approval of Roche’s Alecensa (alectinib) as a treatment for ALK-positive lung…
Roche announced that the China National Drug Administration (CNDA) has granted marketing authorisation for Alecensa (alectinib) as a monotherapy treatment for patients with anaplastic…
Read More...
Read More...
